Pulmonx Corporation
LUNG
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and preā¦ read more
Healthcare
Medical Devices
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.31
Price+2.21%
$0.05
1Y
Price
Market Cap
$97.568m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-38.4%
EBITDA Margin-44.3%
Net Profit Margin-
Free Cash Flow Margin-38.4%
EBITDA Margin-44.3%
Net Profit Margin-
Free Cash Flow MarginRevenue
$87.442m
-3.4%
1y CAGR+8.9%
3y CAGR+13.7%
5y CAGREarnings
-$48.116m
+10.9%
1y CAGR+7.5%
3y CAGR+4.8%
5y CAGREPS
-$1.15
+13.5%
1y CAGR+10.4%
3y CAGR+7.6%
5y CAGRBook Value
$39.196m
$114.732m
Assets$75.536m
Liabilities$56.211m
DebtDebt to Assets
49.0%
-1.3x
Debt to EBITDAFree Cash Flow
-$25.454m
+22.6%
1y CAGR+12.3%
3y CAGR+13.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company